Crescent Innovations announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.
PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease. PgGA, while polyanionic like the current state of the art OA treatment, hyaluronic acid (HA), is unique in its charge density. PgGA has triple the charge density of HA. Crescent Innovations has shown, both in vitro and in vivo, that this allows PgGA to reduce MMPs and other inflammatory marker far greater than HA. PgGA has been tested in disease models and ISO standard bio-compatibility tests.
The company retained advisory firm Alternotio to sell the assets using a sealed bid sales process. The assets will be sold at a sealed bid sale on June 28, 2024, at noon.
“Crescent Innovations has shown, both in vitro and in vivo, that…PgGA…reduce[s] MMPs and other inflammatory marker[s] far greater than HA,” said Al Prescott, President Crescent Innovations Inc.
Crescent Innovations announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.
PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease. PgGA, while polyanionic like the current state of the art OA...
Crescent Innovations announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.
PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease. PgGA, while polyanionic like the current state of the art OA treatment, hyaluronic acid (HA), is unique in its charge density. PgGA has triple the charge density of HA. Crescent Innovations has shown, both in vitro and in vivo, that this allows PgGA to reduce MMPs and other inflammatory marker far greater than HA. PgGA has been tested in disease models and ISO standard bio-compatibility tests.
The company retained advisory firm Alternotio to sell the assets using a sealed bid sales process. The assets will be sold at a sealed bid sale on June 28, 2024, at noon.
“Crescent Innovations has shown, both in vitro and in vivo, that…PgGA…reduce[s] MMPs and other inflammatory marker[s] far greater than HA,” said Al Prescott, President Crescent Innovations Inc.
Copy to clipboard 
